Clinical Trial Update: Adherence to Otezla [EARLY_Phase 1]

View source ↗

Summary

A clinical trial evaluating adherence to Otezla (apremilast) in psoriasis at EARLY_PHASE1 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• OTEZLA (apremilast)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Psoriasis | EARLY_Phase 1 | Status: WITHDRAWN